These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11940467)

  • 41. Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel.
    Markman M; Fowler J
    Gynecol Oncol; 2004 Jan; 92(1):180-2. PubMed ID: 14751155
    [TBL] [Abstract][Full Text] [Related]  

  • 42. North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer.
    Moreno-Aspitia A; Perez EA
    Clin Breast Cancer; 2005 Oct; 6(4):361-4. PubMed ID: 16277889
    [No Abstract]   [Full Text] [Related]  

  • 43. Dose-dense chemotherapy with trastuzumab is an appropriate option.
    Dang C; Norton L; Hudis C
    J Clin Oncol; 2008 Jul; 26(21):3655-6; author reply 3656. PubMed ID: 18640949
    [No Abstract]   [Full Text] [Related]  

  • 44. Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy.
    Fuller CK; Charlson JA; Dankle SK; Russell TJ
    J Am Acad Dermatol; 2010 Oct; 63(4):e83-4. PubMed ID: 20846560
    [No Abstract]   [Full Text] [Related]  

  • 45. Weekly paclitaxel in the adjuvant treatment of breast cancer.
    Aksoy S; Dizdar O; Altundag K
    N Engl J Med; 2008 Jul; 359(3):310; author reply 310-1. PubMed ID: 18642411
    [No Abstract]   [Full Text] [Related]  

  • 46. Beyond platinum for metastatic and recurrent carcinoma of the cervix.
    Tewari KS; Monk BJ
    Onkologie; 2009 Oct; 32(10):552-4. PubMed ID: 19816070
    [No Abstract]   [Full Text] [Related]  

  • 47. Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab.
    González Cao M; Viteri S; Garrán C; Nieto Y; Aristu J; Ponz M; Martín Algarra S
    Clin Transl Oncol; 2007 Feb; 9(2):119-20. PubMed ID: 17329225
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is trastuzumab every three weeks ready for prime time?
    Cobleigh M; Frame D
    J Clin Oncol; 2003 Nov; 21(21):3900-1. PubMed ID: 14507945
    [No Abstract]   [Full Text] [Related]  

  • 49. Weekly paclitaxel in the adjuvant treatment of breast cancer.
    Tsubokura M; Kami M; Komatsu T
    N Engl J Med; 2008 Jul; 359(3):310; author reply 310-1. PubMed ID: 18635438
    [No Abstract]   [Full Text] [Related]  

  • 50. Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer.
    Karachaliou N; Saloustros E; Vamvakas L; Mavroudis D; Georgoulias V
    Ann Oncol; 2010 Aug; 21(8):1729-1730. PubMed ID: 20601370
    [No Abstract]   [Full Text] [Related]  

  • 51. A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229).
    Arlen PM; Pazdur M; Skarupa L; Rauckhorst M; Gulley JL
    Clin Breast Cancer; 2006 Jun; 7(2):176-9. PubMed ID: 16800982
    [No Abstract]   [Full Text] [Related]  

  • 52. [Nasal septum perforation and bevacizumab].
    Bengrine-Lefevre L; Afchain P; Chibaudel B; Gervais H; Tournigand C; De Gramont A; Louvet C
    Rev Med Interne; 2011 Apr; 32(4):e43-5. PubMed ID: 21470582
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recent developments in weekly paclitaxel therapy in lung cancer.
    Akerley W
    Curr Oncol Rep; 2001 Mar; 3(2):165-9. PubMed ID: 11177749
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Future direction of adjuvant chemotherapy for breast cancer following new risk categories of St. Gallen Consensus].
    Osaki A; Saeki T
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():407-13. PubMed ID: 17682185
    [No Abstract]   [Full Text] [Related]  

  • 55. New approach reduces side effects of high-dose chemotherapy for breast cancer.
    Oncology (Williston Park); 1999 Sep; 13(9):1316. PubMed ID: 10509326
    [No Abstract]   [Full Text] [Related]  

  • 56. Disposition of paclitaxel (Taxol) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Hercpetin).
    Furtlehner A; Schueller J; Jarisch I; Ostermann E; Czejka M
    Eur J Drug Metab Pharmacokinet; 2005; 30(3):145-50. PubMed ID: 16250250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer.
    Dirix L; Triebel F
    Future Oncol; 2019 Jun; 15(17):1963-1973. PubMed ID: 30977393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
    Xu C; Ravva P; Dang JS; Laurent J; Adessi C; McIntyre C; Meneses-Lorente G; Mercier F
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):395-406. PubMed ID: 29915982
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer.
    Gota V; Nookala M; Bonda A; Karanam A; Shriyan B; Kembhavi Y; Gurjar M; Patil A; Singh A; Goyal N; Gupta S
    Cancer Med; 2021 May; 10(9):3068-3076. PubMed ID: 33826243
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Two doses of paclitaxel and statistical analysis: try, try, try again.
    Akerley W
    J Clin Oncol; 1997 Jan; 15(1):408-9. PubMed ID: 8996170
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.